) The principal goal of this proposal is to increase the pool of clinical researchers who can conduct translational research studies in Gl Oncology and be able to devote more time to meritorious patient oriented research. The beginning clinical researchers will be mentored to develop patient-oriented research projects capitalizing on new, laboratory based chemotherapeutic treatment and prevention strategies for GI cancers. This proposal will demonstrate that the translational research program in Gl Oncology at USC has unique multidisciplinary interactions and collaborations providing the environment for an efficient mentoring program for beginning clinicians in patient oriented research. The translation research program in Gl Oncology is focusing on molecular determinants of clinical outcome, This program will not only lead to a better understanding of the spectrum of normal tissue toxicity for specific antineoplastic agents that target novel molecular pathways, but also provide a mechanistic evaluation of the effects of the agents on normal and tumor cells. These proposed projects will utilize: 1) the USC/Norris Comprehensive Cancer Center with its unique ethnically diverse patient population in Los Angeles County and the GCRC at the LAC-USC Medical Center; 2) the combined expertise of City of Hope Comprehensive Cancer Center (COH), USC and UC Davis Cancer Center in the areas of molecular pharmacology, pharmacokinetics, pharmacodynamics, cell cycle control and data acquisition to conduct innovative laboratory directed developmental studies supported by CTEP/NCI and 3) our close collaborations and access to clinical protocols from SWOG and CALGB. This proposal will feature three beginning clinicians responsible for three different patient oriented projects taking advantage of our successful program in molecular outcome research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24CA082754-02
Application #
6377419
Study Section
Subcommittee G - Education (NCI)
Program Officer
Gorelic, Lester S
Project Start
2000-09-18
Project End
2005-08-31
Budget Start
2001-09-01
Budget End
2002-08-31
Support Year
2
Fiscal Year
2001
Total Cost
$78,277
Indirect Cost
Name
University of Southern California
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Gordon, Michael A; Zhang, Wu; Yang, Dongyun et al. (2011) Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. Pharmacogenomics 12:27-39
Press, O A; Zhang, W; Gordon, M A et al. (2011) Gender-related survival differences associated with polymorphic variants of estrogen receptor-? (ER?) in patients with metastatic colon cancer. Pharmacogenomics J 11:375-82
Winder, Thomas; Zhang, Wu; Yang, Dongyun et al. (2010) Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients. Clin Cancer Res 16:5591-602
Schneider, Sylke; Park, David J; Yang, Dongyun et al. (2006) Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. Pharmacogenet Genomics 16:555-63
Yang, Dongyun; Schneider, Sylke; Azuma, Mizutomo et al. (2006) Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clin Colorectal Cancer 6:305-11
Vallbohmer, Daniel; Iqbal, Syma; Yang, Dong Yun et al. (2006) Molecular determinants of irinotecan efficacy. Int J Cancer 119:2435-42
Gordon, Michael A; Gil, Ji; Lu, Bo et al. (2006) Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics 7:67-88
Stoehlmacher, J; Park, D J; Zhang, W et al. (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344-54
Stoehlmacher, Jan; Lenz, Heinz-Josef (2003) Implications of genetic testing in the management of colorectal cancer. Am J Pharmacogenomics 3:73-88
Stoehlmacher, Jan; Lenz, Heinz-Josef (2003) Cyclooxygenase-2 inhibitors in colorectal cancer. Semin Oncol 30:10-6